Italian interim analysis of the multinational, post-authorisation safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma: focus on time to onset of adverse events
Year: 2025
Type: article
Abstract: Background: Sonidegib is an oral inhibitor of the hedgehog signalling pathway, approved by EMA in 2015, following the pivotal BOLT study, for the treatment of adult patients with locally advanced BCC (laBCC) not amenable to curative surgery or radiation therapy. This interim analysis presents Italian data from the post-authorization safety NISSO study.
Source: EJC Skin Cancer
Institutions: Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", University of Naples Federico II, IRCCS Humanitas Research Hospital, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Brescia, University of Florence, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, San Gallicano Hospital, Istituti di Ricovero e Cura a Carattere Scientifico, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Istituto Tumori Bari, Ospedale Policlinico San Martino, Istituto Dermopatico dell'Immacolata, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Agostino Gemelli University Polyclinic
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,340
OpenAlex ID: W4409145684